KYNTRA BIO, INC.

KYNBSEC EDGAR

Pharmaceutical PreparationsCIK: 921299

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$46.8M	$235.3M	$176.3M	$256.6M	$213.0M
Cost of Revenue	$4.0M	$12.9M	$8.9M	$1.1M	—
Research and Development Expense	$266.5M	$387.0M	$252.9M	$209.3M	$235.8M
Selling, General and Administrative Expense	$86.5M	$123.9M	$106.4M	$135.5M	$63.8M
Operating Expenses	—	—	—	—	$299.7M
Operating Income (Loss)	-$322.7M	-$288.5M	-$191.9M	-$89.3M	-$86.7M
Interest Expense	$8.1M	$1.1M	$2.4M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$423.5M	$610.1M	$773.8M	$826.8M	$857.4M
Assets, Current	$331.6M	$492.8M	$474.1M	$755.1M	$702.5M
Cash and Cash Equivalents, at Carrying Value	$81.6M	$155.7M	$171.2M	$678.4M	$126.3M
Accounts Receivable, after Allowance for Credit Loss, Current	$5.1M	$16.3M	$17.4M	$41.9M	$28.5M
Inventory, Net	$17.2M	$40.4M	$31.0M	$16.5M	$6.9M
Liabilities	$585.7M	$611.6M	$544.7M	$385.4M	$322.0M
Liabilities, Current	$217.7M	$273.6M	$225.5M	$163.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$315.0M	-$82.2M	$81.6M	-$78.7M	-$76.1M
Net Cash Provided by (Used in) Investing Activities	$153.7M	-$427.0M	$452.5M	$120.0M	-$522.1M
Net Cash Provided by (Used in) Financing Activities	$122.7M	-$563.0K	$13.3M	-$4.3M	$13.9M
Payments to Acquire Property, Plant, and Equipment	$2.5M	$5.2M	$4.0M	$5.8M	$8.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)